← Back to patent-cliff list
CAS 1048002-36-3
Codes: Efatutazone hydrochloride
Application context (from source-drug indications)
脂肪肉瘤Efatutazone hydrochlorideThyroid cancerEfatutazone hydrochlorideAnaplastic thyroid cancerEfatutazone hydrochlorideColorectal cancerEfatutazone hydrochlorideMultiple myelomaEfatutazone hydrochlorideLymphomaEfatutazone hydrochloride
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Efatutazone hydrochloride | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
5-(4-amino-3,5-dimethylphenoxy)-N-methyl-2-nitroaniline→5-(4-amino-3,5-dimethylphenoxy)-N1-methylbenzene-1,2-diamine→2-(4-((2,4-dioxothiazolidin-5-yl)methyl)phenoxy)acetic acid→N-(4-(4-amino-3,5-dimethylphenoxy)-2-(methylamino)phenyl)-2-(4-((2,4-dioxothiazolidin-5-yl)methyl)phenoxy)acetamide→Efatutazone hydrochloride
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.